My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

10.13 +0.40 (+4.11%)

Official Closing Price Updated: 4:15 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company

June 22, 2021

From Blackstone

Via Business Wire

The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs ↗

June 20, 2021

Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries.

Via Talk Markets

The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs ↗

June 20, 2021

Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal...

Via Benzinga

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗

May 01, 2021

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 11, 2021 ↗

June 11, 2021

Upgrades Barclays upgraded the previous rating for Ventas Inc (NYSE:VTR) from Equal-Weight to Overweight. In the first quarter, Ventas showed an EPS of $0.72, compared to...

Via Benzinga

What's the Best Way to Invest in Genetics Stocks? ↗

June 07, 2021

Here are some of our experts' favorite gene editing plays for the long run.

Via The Motley Fool

This Genetics Stock Could Have a Bright Future ↗

June 03, 2021

Here's one genetics play that you might want to put on your radar.

Via The Motley Fool

Biotech Stocks Cruise Through The Volatility ↗

May 25, 2021

The XLV Healthcare Select SPDR is up 10% YTD.

Via Talk Markets

10 Health Care Stocks Showing Unusual Options Activity In Today's Session ↗

May 14, 2021

This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges...

Via Benzinga

Intellia Therapeutics, Inc. (NTLA) Q1 2021 Earnings Call Transcript ↗

May 07, 2021

NTLA earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Benzinga's Top Ratings Upgrades, Downgrades For May 7, 2021 ↗

May 07, 2021

Upgrades Loop Capital upgraded the previous rating for Roku Inc (NASDAQ:ROKU) from Hold to Buy. In the first quarter, Roku showed an EPS of $0.54, compared to $0.45 from...

Via Benzinga

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom ↗

May 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2021 ↗

May 04, 2021

Upgrades For Genuine Parts Co (NYSE:GPC), Goldman Sachs upgraded the previous rating of Sell to Neutral. In the first quarter, Genuine Parts showed an EPS of $1.50,...

Via Benzinga

3 Exciting Biotech Stocks to Buy Right Now ↗

April 30, 2021

Gene therapies could be poised to enter an era of extraordinarily rapid advancement.

Via The Motley Fool

CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today ↗

April 16, 2021

A "sell" rating is one thing, but a 50% price target? It's no wonder Editas stock is crashing, and taking other gene-editing stocks with it.

Via InvestorPlace

The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data ↗

April 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7) Aclaris Therapeutics, Inc...

Via Benzinga

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.